Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00315861 · ClinicalTrials.gov registry record · Phase 1

Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies

A Phase 1 study of Lung Cancer and Ovarian Cancer, sponsored by SCRI Development Innovations.

Completed
Registry status
Phase 1
Development phase
15
Enrollment target
1
Study location

NCT00315861 is a Phase 1 study of Lung Cancer and Ovarian Cancer that has completed, run by SCRI Development Innovations. The registered enrollment target is 15 participants, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00315861, a Phase 1 study of Lung Cancer and Ovarian Cancer, has completed, sponsored by SCRI Development Innovations.

COMPLETED
Registry status
Phase 1
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs to be easily combined. This phase I trial will evaluate the safety and tolerability of weekly topotecan in combination with pemetrexed in patients with advanced solid tumors.

Conditions Studied

Lung Cancer Ovarian Cancer Endometrial Cancer Cervical Cancer

Interventions

  • DRUG pemetrexed
  • DRUG topotecan

Study Locations (1)

Tennessee

  • Tennessee Oncology, PLLC - Nashville

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2006-03
Est. Completion 2009-01
Phase Phase 1

Sponsor

SCRI Development Innovations

146 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00315861

The ClinicalTrials.gov registry entry for NCT00315861 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 936-participant average among 409 other Lung Cancer trials with a reported enrollment target (98% lower). The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which pemetrexed is the first listed.

NCT00315861 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.

Frequently Asked Questions

What is clinical trial NCT00315861 about?

NCT00315861 is a clinical study titled "Topotecan in Combination With Pemetrexed in Patients With Advanced Malignancies". Currently, no data exists regarding the safety and tolerability of a combination regimen utilizing weekly topotecan in combination with pemetrexed. Although both drugs are associated with myelosuppression, it is hoped that the utilization of the weekly topotecan dosing schedule will allow the drugs ...

What is the current status of trial NCT00315861?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2006-03. Estimated completion is 2009-01.

What conditions does trial NCT00315861 study?

This clinical trial studies the following conditions: Lung Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer.

What interventions are being tested in trial NCT00315861?

The interventions under investigation include: pemetrexed (DRUG), topotecan (DRUG).

Who is sponsoring clinical trial NCT00315861?

This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00315861 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Cancer

All registered trials for this condition

Ovarian Cancer

All registered trials for this condition

Tennessee

All trials with a study site in Tennessee

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.